Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Haematol ; 75(4): 346-51, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16146542

ABSTRACT

OBJECTIVES: Accumulating evidence suggests that non-T, non-B cell CD4+CD56+ neoplasms with lymphoblastic morphology include clinically and immunophenotypically diverse entities. Although their cells of origin or classification are still controversial several entities clearly represent a distinct type of neoplasms that are clinically aggressive. METHODS: In this work we present the immunophenotypic and genotypic features of bone marrow (BM), peripheral blood (PB), lymph node and skin lymphocytes from a patient diagnosed as plasmacytoid dendritic cell leukemia involving the skin, BM, PB, lymph nodes, liver and spleen. For determination of immunophenotypic characteristics of malignant plasmacytoid dendritic cells 73 monoclonal antibodies detecting lineage markers, chemokine receptors, cytokine receptors, activation, and co-stimulatory molecules were used. RESULTS AND CONCLUSION: The malignant cells proved to express CD4+, CD56+ lineage negative leukemia phenotype characteristically positive for CD36, CD38, CD40, CD45, CD45RA, CD68, CD123, CD184, HLA-DR, BDCA2, and granzyme-B corresponding to the preplasmacytoid dendritic cell developmental stage. The presence of CD11a/CD18, CD84, CD91, CD95, alphavbeta5, CDw197, and the absence of CD52 and CD133 in this case can be regarded as additional features of malignant cells. Completing the immunophenotypes with multidrug resistance function can provide additional information for characterizing pDC leukemia.


Subject(s)
Dendritic Cells/pathology , Leukemia/pathology , Plasmacytoma/pathology , Aged , Blood Cells/pathology , CD4 Antigens , CD56 Antigen , Cell Lineage , Flow Cytometry , Humans , Immunophenotyping , Lymph Nodes/pathology , Male , Skin/pathology
2.
Cancer Immunol Immunother ; 53(9): 835-9, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15052374

ABSTRACT

The aim of this study was to determine the complement functions, the serum levels of the complement components C3 and C4, and circulating immune complexes during autologous blood stem cell transplantation. Seventeen lymphoma patients receiving transplants between 1997 and 2001 were involved in this study. High-dose chemotherapy with or without total body irradiation was used for conditioning. The transplantation resulted in complete remission without complications in 14 patients. Early relapse developed in one case and two nonrelapsed patients suffered from serious toxic infection early posttransplant. Normal values of CH50, C3, C4, and immune complexes in sera of patients were detected on day -7, before the conditioning (day of transplantation was determined as day 0). After the conditioning, on day -2, the levels of the CH50, C3, and C4 decreased significantly ( p<0.05) in all patients compared with the starting values. The CH50, C3, and C4 levels exceeded the starting values in the noninfected patients from day +7. In two patients suffering from toxic infection, significantly elevated complement levels were documented early posttransplant. In the relapsed patient a significant decrease of the complement parameters was documented posttransplant accompanied by a significant elevation in the immune complex level. The results show alteration in the complement parameters during transplantation, but in the complication-free cases this remained within the normal ranges. However, an unusual elevation seemed to be the sign of infection, and the significant decrease seemed to indicate a relapse.


Subject(s)
Antigen-Antibody Complex/metabolism , Complement C3/metabolism , Complement C4/metabolism , Hodgkin Disease/metabolism , Lymphoma, Non-Hodgkin/metabolism , Stem Cell Transplantation , Adult , Complement Hemolytic Activity Assay , Female , Hodgkin Disease/immunology , Hodgkin Disease/therapy , Humans , Lymphoma, Non-Hodgkin/immunology , Lymphoma, Non-Hodgkin/therapy , Male , Middle Aged , Transplantation Conditioning , Transplantation, Autologous , Whole-Body Irradiation
3.
Rheumatol Int ; 24(6): 359-61, 2004 Nov.
Article in English | MEDLINE | ID: mdl-14986060

ABSTRACT

The authors report a rare case of a female patient diagnosed with mixed connective tissue disease (MCTD). After a few years in remission, the patient acquired herpes zoster infection followed by a disease flare. Disease activity was accompanied by the development of meningitis. To determine whether the meningitis was caused by the previous herpes virus infection or was aseptic meningitis associated with the activity of MCTD raised important differential diagnostic issues. Repeated laboratory assessments of the patient's sera and cerebrospinal fluid revealed leukocytopenia, high anti-U1 ribonucleoprotein autoantibody level, increased immune complex, and decreased complement concentrations. The administration of corticosteroids resulted in rapid improvements in clinical symptoms and laboratory indicators.


Subject(s)
Herpes Zoster/diagnosis , Meningitis, Aseptic/diagnosis , Mixed Connective Tissue Disease/diagnosis , Adrenal Cortex Hormones/therapeutic use , Adult , Female , Follow-Up Studies , Herpes Zoster/drug therapy , Herpes Zoster/epidemiology , Humans , Meningitis, Aseptic/complications , Meningitis, Aseptic/drug therapy , Mixed Connective Tissue Disease/complications , Mixed Connective Tissue Disease/drug therapy , Risk Assessment , Severity of Illness Index , Treatment Outcome
4.
Pathol Oncol Res ; 9(2): 131-3, 2003.
Article in English | MEDLINE | ID: mdl-12858220

ABSTRACT

Relapse is the main cause of treatment failure following hematopoietic stem cell transplantation for blastic phase chronic myeloid leukemia. Treatment options including donor lymphocyte infusion, second transplantation, interferon- and re-induction chemotherapy are often unsuccessful. We report a patient with blastic phase chronic myeloid leukemia relapsing after allogeneic stem cell transplantation. The post-transplant leukemia was characterized with B-lymphoid markers and multiple genetic abnormalities including double Ph-chromosomes. The disease was treated with three courses of salvage chemotherapy combined with donor lymphocyte infusion and bcr-abl tyrosine kinase inhibitor. The leukemia proved to be non-responsive both to immune therapy and STI 571. The presented case demonstrates the need for combination approaches in post-transplant relapsed leukemia and discusses the possible contributing mechanisms of STI-571 resistance.


Subject(s)
Blast Crisis/therapy , Bone Marrow Transplantation , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Leukocyte Transfusion , Piperazines/therapeutic use , Pyrimidines/therapeutic use , Antineoplastic Agents/therapeutic use , B-Lymphocytes/pathology , Benzamides , Drug Resistance, Neoplasm , Enzyme Inhibitors/therapeutic use , Fusion Proteins, bcr-abl/antagonists & inhibitors , Humans , Imatinib Mesylate , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Male , Middle Aged , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/therapy , Protein-Tyrosine Kinases/antagonists & inhibitors , Remission Induction , Salvage Therapy , Tissue Donors , Transplantation, Homologous , Treatment Outcome
5.
Acta Microbiol Immunol Hung ; 50(1): 55-65, 2003.
Article in English | MEDLINE | ID: mdl-12793201

ABSTRACT

Reaction patterns of the 7th Human Leukocyte Differentiation Antigen Workshop blind panel adhesion molecules were studied on CD3/CD4, CD3/CD8, CD3/TCR gamma delta double positive T cells from peripheral blood of patients with chronic graft versus host disease (n = 8) and healthy controls (n = 4). Reactivity of 14 adhesion antibodies was tested by three-colour immunophenotyping. The mean proportion of CD3+ T cells (69 +/- 19%). CD3/CD8++ (31 +/- 13%) and CD3/TCR gamma delta++ (4 +/- 2%) T sub-populations of patients were comparable with the healthy controls. However, the mean percentage of CD3/CD4++ T cell subset in patients (14 +/- 12%) proved to be significantly decreased in comparison with the normal control value (34 +/- 16%) presumably due to secondary immunodeficiency. The workshop antibodies proved to be reactive with three T cell subsets expressing the examined antigens. Based on the results of the adhesion molecule workshop new CD categories have been introduced: CD156b as a transmembrane protein, CD167a as an epithelial tyrosin kinase receptor, CD168 as a receptor for hyaluronan mediated motility (RHAMM) and CD171 as a co-stimulatory adhesion molecule. There were significant differences in the expression of the CD167a and CD156b antigens on the CD3/CD4++ subset between the samples of patients compared with the controls characterizing the CD4+ T lymphocyte subpopulation in chronic graft versus host disease.


Subject(s)
Antigens, CD/metabolism , Graft vs Host Disease/immunology , Membrane Proteins , Receptors, Antigen, T-Cell, gamma-delta/metabolism , T-Lymphocyte Subsets/immunology , ADAM Proteins , Adult , CD3 Complex/metabolism , CD4 Antigens/metabolism , CD8 Antigens/metabolism , Chronic Disease , Extracellular Matrix Proteins/metabolism , Female , Hematopoietic Stem Cell Transplantation , Humans , Hyaluronan Receptors/metabolism , Immunophenotyping , Male , Metalloendopeptidases/metabolism , Middle Aged , T-Lymphocyte Subsets/metabolism , Transplantation, Homologous
6.
Cytokine ; 18(6): 340-3, 2002 Jun 21.
Article in English | MEDLINE | ID: mdl-12160523

ABSTRACT

We have investigated the influence of apo(a) genetics on the relationship between interleukin (IL)-6, and lipoprotein (a) [Lp(a)] levels in 154 patients with monoclonal gammopathy and 189 healthy subjects. No significant differences in Lp(a) levels and distribution of subjects with different sizes of apo(a) isoforms were found between patients and healthy controls. Relationship between IL-6 and Lp(a) levels was strongly dependent on the size of apo(a) isoforms. In patients with high-size apo(a) isoforms Lp(a) levels positively correlated (r=0.475, P=0.0007) to IL-6 concentrations, whereas no correlation was found in patients with low apo(a) isoforms. Our present finding may provide a plausible explanation for the contradictory findings about the acute phase protein nature of Lp(a).


Subject(s)
Apolipoproteins A/biosynthesis , Apolipoproteins A/chemistry , Interleukin-6/biosynthesis , Lipoprotein(a)/biosynthesis , Paraproteinemias/metabolism , Adult , Aged , Case-Control Studies , Enzyme-Linked Immunosorbent Assay , Female , Humans , Interleukin-6/blood , Male , Middle Aged , Multiple Myeloma/metabolism , Polymorphism, Genetic , Protein Isoforms , Waldenstrom Macroglobulinemia/metabolism
7.
Haematologia (Budap) ; 32(4): 519-27, 2002.
Article in English | MEDLINE | ID: mdl-12803128

ABSTRACT

An unusual case of hepatosplenic gamma delta T-cell lymphoma with leukemic phase in a 39-year-old woman is reported. At the first presentation she had splenomegaly and pancytopenia diagnosed as hypersplenia treated by splenectomy. Subsequently, she developed hepatomegaly and progressive neoplastic lymphocytosis. The bone marrow showed a sinusoidal infiltrate of medium-sized cells. Flowcytometric analysis of peripheral blood mononuclear cells demonstrated expression of CD3, CD7, CD16, CD56 antigens and T-cell receptor gamma delta. A monoclonal TCR gamma- and beta-chain gene rearrangement were detected by polymerase chain reaction. The patient was treated by traditional chemotherapy and alpha-interferon, unsuccessfully. Therefore, 2-chlorodeoxyadenosine was introduced resulting in a complete remission for 6 months. The reported case demonstrates the usefulness of 2-chlorodeoxyadenosine in treatment of hepatosplenic gamma delta T-cell lymphoma.


Subject(s)
Antineoplastic Agents/therapeutic use , Cladribine/therapeutic use , Lymphoma, T-Cell/drug therapy , Lymphoma, T-Cell/immunology , Receptors, Antigen, T-Cell, gamma-delta/metabolism , Adult , Female , Hepatomegaly/drug therapy , Humans , Lymphoma, T-Cell/pathology , Recurrence , Remission Induction , Splenomegaly/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...